There was no elevation in serum ALT levels on day 7 of infection in samples collected from parallel treated and infected hamsters receiving DEF201 (Figure 2A ). Eighty percent of the rAd EV group and 100% of the PBS placebo group had elevated levels of ALT, reflective of liver disease. Interestingly, the 10 7 and 10 8 pfu DEF201 groups presented with little to no day-7 virus burden in the serum, liver, or spleen, while the 10 6 group developed viral titers that were comparable to the rAd EV and placebo controls ( Figure 2B-D) . A delay in the development of liver disease in the 10 6 pfu DEF201treated animals may explain the reduced ALT levels. Alternatively, saturation of liver virus titers in the low-dose DEF201, rAd EV, and placebo groups may have masked a substantial difference between the former and the viral vector and vehicle control groups.